Purpose: Our aim was to assess oncologic, safety, and quality of life-related outcomes of focal therapy with irreversible electroporation in men with localized prostate cancer.
Materials And Methods: This was a single-center, phase II study.
Inclusion Criteria: prostate cancer International Society of Urological Pathology grade 1-2, prostate specific antigen ≤15 ng/ml, ≤cT2b. Patients were selected based on multiparametric magnetic resonance imaging and transperineal systematic and targeted magnetic resonance imaging-ultrasound fusion-guided biopsy. Ablation of index lesions with safety margin was performed. Primary end point was cancer control, defined as the absence of any biopsy-proven tumor. A control transperineal biopsy was planned at 12 months and when suspected based on prostate specific antigen and/or multiparametric magnetic resonance imaging information. Quality of life was assessed using Expanded Prostate Cancer Index Composite Urinary Continence domain, International Index of Erectile Function, and International Prostate Symptom Score.
Results: From November 2014 to July 2021, 41 consecutive patients were included with a median follow-up of 36 months. Thirty patients (73%) had International Society of Urological Pathology grade 1 tumors, 10 (24%) grade 2, and 1 (2.4%) grade 3. Recurrence was observed in 16 of 41 (39%) of the whole cohort, and 16 of 33 (48.4%) who underwent biopsy. In-field recurrence was detected in 5 (15%) and out-of-field in 11 (33.3%). Ten of 41 (24.6%) including 3 of 5 (60%) with in-field recurrences had significant tumors (Gleason pattern 4-5; more than 1 core or any >5 mm involved). Median recurrence-free survival was 32 months (95% CI 6.7-57.2). Twenty-six patients (63.4%) were free from salvage treatment. All patients preserved urinary continence. Potency was maintained in 91.8%.
Conclusions: Irreversible electroporation can achieve satisfactory 3-year in-field tumor control with excellent quality of life results in selected patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JU.0000000000002970 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prostate-specific antigen testing in the United States during 2008-2022 in relation to the US preventive services task force recommendations.
Sci Rep
December 2024
Department of Public Health, College of Life Sciences, Brigham Young University, 2063 Life Sciences Building, Provo, UT, 84602, USA.
The prevalence of prostate-specific antigen (PSA) testing has consistently fallen for several years. This study explored how the decreasing trend differs by selected variables and reasons for taking the PSA test. Analyses involved men, aged 40 years or older, who completed the Behavior Risk Factor Surveillance System (BRFSS) survey in even number years from 2008 through 2022.
View Article and Find Full Text PDFPerioperative Benzodiazepine Exposure Impacts Risk of New Persistent Benzodiazepine Use Among Patients with Cancer.
Ann Surg Oncol
December 2024
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Background: Benzodiazepines are the third most misused medication, with many patients having their first exposure during a surgical episode. We sought to characterize factors associated with new persistent benzodiazepine use (NPBU) among patients undergoing cancer surgery.
Patients And Methods: Patients who underwent cancer surgery between 2013 and 2021 were identified using the IBM-MarketScan database.
Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies.
Prostate Cancer Prostatic Dis
December 2024
Department of Radiation Oncology, Peking University First Hospital, 100034, Beijing, China.
Background: Metastatic prostate cancer (PCa) has much lower survival and ultimately develops castration resistance, which expects novel targets and therapeutic approaches. As a result of iron-dependent lipid peroxidation, ferroptosis triggers programmed cell death and has been associated with castration-resistant prostate cancer (CRPC).
Subjects: To better understand how ferroptosis can be used to treat CRPC, we reviewed the following: First, ferroptosis mechanisms and characteristics.
Application of mobile internet management in the continuing care of patients after radical prostatectomy.
Sci Rep
December 2024
Clinical Nursing Teaching and Research Section, The Second XiangYa Hospital, Central South University, No139, Renmin Road, Changsha, 410011, China.
Prostate cancer, a common malignancy in older men, often requires laparoscopic radical prostatectomy, considered the gold standard treatment. However, postoperative complications can significantly impact quality of life and psychological well-being. The emergence of mobile internet health management offers a promising approach for accessible and effective post-discharge care.
View Article and Find Full Text PDFInsights into glucose-derived carbon dot synthesis via Maillard reaction: from reaction mechanism to biomedical applications.
Sci Rep
December 2024
Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul, 03722, South Korea.
Carbon dots (CDs) are versatile nanomaterials that are considered ideal for application in bioimaging, drug delivery, sensing, and optoelectronics owing to their excellent photoluminescence, biocompatibility, and chemical stability features. Nitrogen doping enhances the fluorescence of CDs, alters their electronic properties, and improves their functional versatility. N-doped CDs can be synthesized via solvothermal treatment of carbon sources with nitrogen-rich precursors; however, systematic investigations of their synthesis mechanisms have been rarely reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!